Thus, while GLP-1R agonists are commonly used for type II diabetes and obesity, there is a growing body of evidence about their role in mediating the effects of other conditions involving inflammatory pathways, including asthma, atherosclerosis, neurogenerative disorders, and myopathies [17,18]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.